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The expression of selected metalloproteinases and
tissue inhibitors of metalloproteinases (TIMP) was
examined in three squamous cell carcinoma (SCC)
cell lines (FaDu, SiHa, A431) and a keratinocyte cell
line (HaCaT) to determine which metalloproteinases
function in SCC invasiveness. A Matrigel invasion
assay was used to assess invasiveness of the cell lines.
Only the FaDu cell line showed invasiveness in this
assay, and invasion of Matrigel by FaDu cells was
inhibited by treatment with the metalloproteinase
inhibitor, batimastat. No correlation was found
between mRNA expression for matrilysin, stromely-
sins 1±3, TIMP-1, or TIMP-3 and secretion of these
proteins, indicating that the extracellular activity of
these molecules is regulated post-transcriptionally.
The SCC cell lines differed from the HaCaT line in
that matrilysin and TIMP-1 proteins were detected
in conditioned medium from all SCC cell lines, but
not in medium from HaCaT cells. Only the invasive
cell line, FaDu, released active stromelysin-1 into the
culture medium. These results indicate that while
matrilysin contributes to the invasive phenotype,
activation of stromelysin-1 is a key regulatory step




n order to migrate into the stroma, invade other tissues, and
metastasize, epithelioid tumor cells must digest and migrate
through their basal lamina and then pass through the
extracellular matrix of surrounding stromal tissue
(Woodhouse et al, 1997). Proteolysis of the basal lamina
and extracellular matrix results from the action of metalloprotei-
nases produced by both tumor cells and surrounding stromal cells
(Kleiner and Stetler-Stevenson, 1999). Gene transfer experiments
have consistently shown that increased metalloproteinase activity is
associated with increased invasiveness of tumor cells (reviewed in
Knox et al, 1998), but metalloproteinases have also been shown to
affect cell proliferation and tumorigenesis (Meade-Tollin et al,
1998; Boulay et al, 2001). Consequently, inhibitors of metallopro-
teinases are being tested for their therapeutic effects on tumor
development, growth, invasiveness, and metastasis.
Batimastat is a general matrix-metalloproteinase inhibitor that
suppresses extracellular matrix degradation in vitro and reduces the
growth of solid tumors in mice (Rasmussen and McCann, 1997).
Batimastat resembles metalloproteinase substrates and acts by
competitive inhibition of metalloproteinase activity, but has no
effect on metalloproteinase expression, cell viability, or cell
proliferation (Chirivi et al, 1994; Sledge et al, 1995; Rasmussen
and McCann, 1997). Batimastat treatment has been shown to
signi®cantly reduce invasiveness of malignant human glioma cells
(Tonn et al, 1999) and neoplastic human prostate cells (Knox et al,
1998) in Matrigel invasion assays. Studies on mouse models have
demonstrated that Batimastat also reduces the incidence of intestinal
tumors (Heppner-Goss et al, 1998), inhibits metastasis of human
breast cancer cells (Sledge et al, 1995), reduces tumor growth and
enhances survival in mice bearing human ovarian tumor grafts
(Davies et al, 1993), and prevents metastasis of human pancreatic
cancer xenografts (Rasmussen and McCann, 1997). Research on
prostate tumors and pancreatic xenografts indicates that metallo-
proteinase inhibition by batimastat allows tumor cells to reform a
basal lamina, thereby limiting invasiveness (Rasmussen and
McCann, 1997; Knox et al, 1998). The effects of batimastat on
squamous cell carcinoma (SCC) have not been described.
Expression of the metalloproteinase matrilysin (MMP-7) is not
found in epidermal or stromal cells in normal skin, but in skin
cancer, matrilysin is expressed by tumor cells at the stromal
interface in SCC, and in aggressive and recurrent morpheaform and
in®ltrative basal cell carcinomas (BCC). Nodulocystic, keratotic,
and adenoid BCC, which are not invasive, do not express
matrilysin (Karelina et al, 1994). Matrilysin is released from the
cell as an inactive proenzyme that is cleaved to yield an active
protein (Woessner, 1991). In addition, transformation of HaCaT ±
a nontumorigenic, noninvasive, keratinocyte cell line ± with c-
rasHa gives rise to tumorigenic cells with increased expression and
secretion of promatrilysin (Meade-Tollin et al, 1998).
Another family of metalloproteinases, the stromelysins, promote
tumor growth through different mechanisms. Stromelysin-1
(MMP-3) digests extracellular matrix proteins and cleaves proma-
trilysin, releasing active matrilysin (Imai et al, 1995; Tsukifuji et al,
1999). Like matrilysin, stromelysin-1 is not expressed by keratino-
cytes in normal skin, but is highly expressed in SCC, and is
expressed by keratinocytes after wounding (Muller et al, 1991;
Saarialho-Kere et al, 1994; Kusukawa et al, 1996; Tsukifuji et al,
1999). Stromelysin-2 (MMP-10) is synthesized by SCC cells, but is
associated with in¯ammation and wound healing rather than
invasiveness (KerkelaÈ et al, 2001; Madlener et al, 1996).
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Stromelysin-3 (MMP-11) does not digest extracellular matrix.
Instead of stimulating invasiveness through matrix degradation,
stromelysin-3 inhibits cell death in malignant cells, thus promoting
tumor growth (NoeÈl et al, 2000; Boulay et al, 2001).
Metalloproteinase activity is inhibited by the tissue inhibitors of
metalloproteinases (TIMP) (Kleiner and Stetler-Stevenson, 1999).
TIMP proteins bind metalloproteinases with 1:1 stoichiometry and
form noncovalent complexes (Umenishi et al, 1991; Gomis-Ruth et
al, 1997). TIMP binding not only inhibits the activity of active
metalloproteinases, but also suppresses conversion of pro-metallo-
proteinase molecules to their active forms (Umenishi et al, 1991). In
normal skin, TIMP-3 and matrilysin exhibit the same patterns of
expression, suggesting that TIMP-3 regulates matrilysin activity in
skin (Airola et al, 1998).
This study was performed to determine whether Batimastat
inhibits invasiveness in SCC cells and to determine which
metalloproteinases regulate invasiveness in SCC cells.
MATERIALS AND METHODS
Cell culture Cell lines used in this study were HaCaT, an
immortalized, nontumorigenic keratinocyte cell line (Boukamp et al,
1988, 1990); SiHa, a SCC from the cervix (ATCC HTB-35, American
Type Culture Collection, Rockville, MD); FaDu, a SCC from the
pharynx (ATCC HTB-43); and A431, a metastatic SCC from the
epidermis (ATCC CRL-1555). Each cell line was maintained in D-
MEM/F-12 medium (Gibco-BRL, Grand Island, NY) containing 3%
fetal bovine serum (Gibco-BRL), 80 units penicillin per ml, and 80 mg
streptomycin per ml (Gibco-BRL). Cultures were grown in a humidi®ed
incubator at 37°C, 5% CO2 in air.
Matrigel invasion assay The invasion assay was adapted from the
method described by Kawahara et al (1995). Chambers were prepared for
invasion assays by coating porous (8 mm pores) tissue culture inserts
(Falcon, Franklin Lakes, NJ) with 90 mg per cm2 of Matrigel (Becton
Dickinson Labware, Bedford, MA) suspended in phosphate-buffered
saline (PBS; Sigma, St. Louis, MO). Inserts were placed in a 24 well
plate containing medium with 10% fetal bovine serum, which stimulates
cell migration. Cells were plated on the inserts at 5 3 104 cells per insert
in serum-free medium. For control experiments, cells were plated in
serum-free medium on inserts that were not coated with Matrigel. Cells
were incubated for 24 h, then ®xed and stained with Diff-Quick (Dade
Behring, Newark, DE). Each assay was performed in triplicate. For each
cell line the number of cells passing through uncoated and Matrigel-
coated ®lters were counted. Cells on each insert were viewed with a
Zeiss Axioscop microscope, and counted in 30 optical ®elds
(2.5 3 2.5 mm grid) at 403 magni®cation. Statistical signi®cance was
determined using a one-tailed t-test for samples of unequal variance.
To assess the effects of Batimastat (BB-94, British Biotech
Pharmaceuticals, Oxford, U.K.) on invasion of Matrigel, cells were
plated on inserts in serum-free medium containing 0.1 or 1.0 mM
Batismastat and incubated for 24 h before counting as described.
Semiquantitative reverse transcriptase-polymerase chain reaction
(RT-PCR) Total RNA was extracted from cells using the Qiagen
RNeasy kit (Valencia, CA). RNA 100 ng was ampli®ed by RT-PCR,
using the Titan kit (Roche Biochemicals, Indianapolis, IN). The RT-
PCR program was as follows: one cycle of 50°C for 30 min, 90°C for
2 min; 15 cycles of 90°C for 1 min, 55°C for 30 min, 68°C for 1 min;
10 cycles of 90°C for 1 min, 58°C for 30 min, 68°C for 1 min; one
cycle of 68°C for 4 min. Primers for human matrilysin were 5¢-
GAACAATTGTCTCTGGACGG and 3¢-TTGGCTTCTACTGTT-
GGC. Primers for human TIMP-1 were 5¢-GACTCTTGCACATCAC-
TAC and 3¢-ACACTGTGCAGGCTTCAGT. Primers speci®c for
human TIMP-3 were 5¢-AATGACCCCTTGGCTCGG and 3¢GGT-
GTAGACCAGCGTGCC. Primers for human stromelysin-1 were 5¢-
AAGAGCAACGACGAGTACTT and 3¢-AGGTCCTTGCTAGTAA-
CTTCA. Human stromelysin-2 primers were 5¢-AGCTAGACACT-
GACACTCTG and 3¢-TGCCTGATGCATCTTCTGTC. Human
stromelysin-3 primers were 5¢-TCGACTATGATGAGACCTG and 3¢-
CAGTCTGAGACAGTCGCTG. RT-PCR products were separated on
a 2% SeaKem agarose gel (FMC, Rockland, ME), detected with Sybr
Green I (FMC) and analyzed with a FluoroImager (Molecular Dynamics,
Sunnyvale, CA). Semiquantitative evaluation of expression was
performed by comparison with expression of the GADPH gene in the
same sample. Primers for human GAPDH were 5¢-ACAGTCCA-
TGCCATCACTGCC and 3¢-GCCTGCTTCACCACCTTCTTG.
Immunoblotting Levels of metalloproteinase and TIMP proteins
were analyzed in conditioned medium by immunoblotting. For
conditioned medium samples, each cell line was grown in serum-free
medium for 48 h. The culture medium was then collected, concentrated
10-fold with Millipore Ultrafree-probind membrane ®lters (Millipore,
Bedford, MA), and stored at ±80°C. For each sample, 30 mg of protein
was loaded onto a 4%±20% gradient SDS-polyacrylamide gel (FMC) in
reducing buffer (Laemmli buffer, Bio-Rad Laboratories, Hercules, CA)
and electrophoresed at 70 V. Colored molecular weight markers
(Rainbow markers, Amersham-Pharmacia, Piscataway, NJ) were run on
each gel. The proteins were transferred to Immobilon-P membrane
(Millipore) for immunostaining. Membranes were blocked for 1 h at
room temperature with 10% fat free milk in TBS (20 mM Tris, 150 mM
NaCl, pH 7.4) containing 0.1% Tween-20, then incubated for 90 min
with primary antibody diluted in TBS-0.1% Tween-20. After washing,
the membranes were incubated with horseradish peroxidase-conjugated
secondary antibody (Amersham-Pharmacia) for 45 min. Antibody
binding was detected using enhanced chemiluminescence (Amersham-
Pharmacia).
Immunocytochemistry To synchronize the cell cultures for mitosis,
all cell lines were treated with 4.0 mg aphidicolin per ml for 8 h.
Medium was then replaced to wash out the aphidicolin and cells were
®xed for immunocytochemistry at 2, 4, 8, 12, 16, and 24 h after
removal of aphidicolin. For antibody labeling, cells were ®xed with ice-
cold 50% acetone in methanol, washed with PBS, washed twice with 5%
bovine serum albumin in PBS, then incubated with primary antibodies at
4°C overnight. Samples were washed three times with 0.5% bovine
serum albumin in PBS, then incubated with secondary antibodies for 1 h
at room temperature. After washing, DNA was stained with 100 ng
DAPI (4,6-diamidino-2-phenylindole) per ml (Sigma). DNA staining
was used to identify mitotic cells.
All primary antibodies for immunoblotting and immunocytochemistry
were mouse monoclonal antibodies obtained from Oncogene Research
Products (Boston, MA). Speci®cally, these were IM40T, MMP-7 (Ab-1)
speci®c for promatrilysin; IM47T, MMP-7 (Ab-2) speci®c for active
matrilysin; IM69T, MMP-3 (Ab-4) speci®c for pro- and active
stromelysin-1; IM75T, MMP-10 (Ab-2) speci®c for pro- and active
stromelysin-2; IM86T, MMP-11 (Ab-2) speci®c for pro- and active
MMP-11; IM68T, MMP-2 (Ab-8) speci®c for pro- and active gelatinase
A; IM37T, MMP-9 (Ab-3) speci®c for pro- and active gelatinase B;
IM63T, TIMP-1 (Ab-4); IM82T, TIMP-2 (Ab-4); IM43T, TIMP-3
(Ab-1). Secondary antibodies for immunocytochemistry were conjugated
with Texas Red or FITC and obtained from Jackson ImmunoResearch
Laboratories (West Grove, PA).
RESULTS
Invasion assays were performed to determine whether cell
invasiveness correlates with the production of matrilysin or other
metalloproteinases. Invasiveness was measured as the ability of cells
to digest Matrigel. The four cell lines differed in ability to pass
through uncoated ®lters, indicating inherent differences in cell
mobility (Fig 1a). The number of FaDu cells passing through
uncoated ®lters was signi®cantly (p < 0.05) greater than the number
of HaCaT cells crossing uncoated ®lters. HaCaT and SiHa cell lines
exhibited both poor cell mobility and Matrigel invasion. A431 cells
demonstrated greater mobility and Matrigel invasion than HaCaT
and SiHa cells, although assay results did not reach statistical
signi®cance.
Treatment with the inhibitor Batimastat at 0.1 mM reduced by
half the mean number of FaDu or HaCaT cells passing through
uncoated ®lters (Fig 1a). Treatment with 1.0 mM Batimastat
reduced by at least half the number of HaCaT, FaDu, or A431
cells traversing uncoated ®lters, but mobility of treated cells was
signi®cantly different from untreated cells only in the HaCaT cell
line (Fig 1a). Batimastat treatment had no effect on the mobility of
SiHa cells (Fig 1a). On Matrigel-coated ®lters, both FaDu and
A431 cells were active in digesting Matrigel; however, FaDu cells
were four times more active than A431 in invading the Matrigel
(Fig 1b). The number of FaDu cells traversing Matrigel-coated
®lters was signi®cantly (p < 0.05) greater than the number of
HaCaT cells passing through the Matrigel. HaCaT and SiHa
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showed only weak invasion of Matrigel (Fig 1b). Batimastat at
1.0 mM signi®cantly inhibited Matrigel invasion by FaDu cells
(Fig 1b). These results show that the FaDu cell line is the only
SCC line tested that readily invades Matrigel, and that inhibition of
metalloproteinase activity inhibits Matrigel invasion by FaDu cells.
To determine if invasiveness and expression of metalloproteinase
or TIMP mRNA are correlated, steady-state levels of mRNA for
matrilysin, stromelysins-1, 2, and 3, and TIMP-1 and -3 in each cell
line were measured by semiquantitative RT-PCR. These results
are shown in Fig 2. Only mRNA for stromelysin-2 was higher in
the FaDu cell line than in the other cell types, and the difference
was not substantial. The four cell lines expressed similar levels of
mRNA for matrilysin, stromelysin-3, and TIMP-1 (Figs 2a, b).
Stromelysin-2 mRNA was the most abundantly expressed
stromelysin RNA in all four cell lines (Fig 2a). TIMP-3 mRNA
levels were nearly 2-fold greater in HaCaT and A431 cells than in
SiHa or FaDu cells (Fig 2c). These results do not reveal a clear
correlation between invasiveness in Matrigel and steady-state RNA
levels for matrilysin, stromelysins-1±3, or TIMP-1 or -3.
Immunoblotting was performed to examine the levels of
metalloproteinases and TIMP released into the culture medium
by each cell line. These results are shown in Fig 3. Conditioned
medium from FaDu and A431, the cell lines with greatest mobility,
contained the highest amounts of both promatrilysin and active
matrilysin. Both forms were present in lesser amounts in medium
from SiHa cells, but neither form was detected in conditioned
medium from HaCaT cells. A similar pattern was seen for TIMP-1:
FaDu and A431 cells produced the greatest amounts of TIMP-1,
SiHa cells produced a lesser amount, and no TIMP-1 was detected
in medium from HaCaT cells. Neither TIMP-2 nor TIMP-3 could
be detected in conditioned medium from any of the cell lines.
These results suggest that TIMP-1 regulates the activity of secreted
matrilysin in these cell lines.
FaDu and A431 medium also contained the highest amounts of
prostromelysin-1, but only medium from FaDu cells contained a
substantial level of active stromelysin-1. FaDu cells also produced
greater amounts of active stromelysin-2 and active stromelysin-3
than the other three cell lines. Stromelysin 2 was easily detected in
medium from HaCaT and A431 cells, but only weakly detectable
in medium from SiHa cells. Stromelysin 3 was weak in HaCaT,
SiHa, and A431 cell medium. Medium from FaDu and A431 cells
contained the highest amounts of active gelatinase A, but strong
labeling for gelatinase A was also seen in SiHa and HaCaT cells. In
contrast, active gelatinase B (MMP-9) was clearly present in
Figure 1. Effect of batimastat on cell
invasiveness and motility. Cells were plated on
uncoated or Matrigel-coated porous ®lters. After a
24 h incubation, the cells were stained and the
number of cells passing through the ®lters was
determined. Each assay was performed in
triplicate. Mean and SD for ®ve assays of each cell
line for untreated cells, two assays for 0.1 mM
batimastat (BB-94), and four assays at 1.0 mM
batimastat. (a) Number of cells passing through
uncoated ®lters. For untreated SCC cells
compared with untreated HaCaT, p = 0.07 for
SiHa, 0.04 for FaDu*, 0.06 for A431. For
treatment with 1.0 mM batimastat compared with
untreated cells, p = 0.03 for HaCaT**, 0.29 for
SiHa, 0.15 for FaDu, 0.13 for A431. *Statistically
signi®cant (p < 0.05) difference compared with
untreated HaCaT; **statistically signi®cant
difference for batimastat-treated compared with
untreated cells of the same cell line. (b) Invasion
of Matrigel-coated ®lters. Untreated SCC versus
untreated HaCat, p = 0.20 for SiHa, 0.02 for
FaDu*, 0.10 for A431. Batimastat at 1.0 mM
compared with untreated cells, p = 0.40 for
HaCaT, 0.09 for SiHa, 0.02 for FaDu**, 0.09 for
A431.
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medium from HaCaT and SiHa cells, the cell lines with poor
mobility, but was barely detectable in medium from FaDu and
A431 cells. Thus, only secretion of active stromelysin-1 and
stromelysin-3 correlates with the invasive phenotype exhibited by
the FaDu cell line, whereas gelatinase A and matrilysin secretion is
associated with cell mobility and the SCC phenotype.
Cellular expression of active matrilysin re¯ected the release of
matrilysin into culture medium. Antibody labeling revealed little or
no active matrilysin in HaCaT cells, except in mitotic cells
(Fig 4a). In contrast, SiHa, FaDu, and A431 cells were strongly
labeled for active matrilysin in nondividing and mitotic cells
(Figs 4b±d). In all cell lines, labeling for active matrilysin was
localized around the perimeter of the nucleus and may be associated
with the endoplasmic reticulum. Stromelysin-1 labeling was
similarly greater in the SCC lines than in HaCaT cells, and
exhibited the same cellular localization as matrilysin (Fig 5).
Although TIMP-1 was not found in medium from HaCaT cells,
cell-associated TIMP-1 was detected by antibody labeling in
HaCaT cells, as well as in the three SCC cell lines (Fig 6). TIMP-1
labeling was greatest in A431 cells (Fig 6d). In the three SCC cell
lines, TIMP-1 labeling was concentrated around the nuclear
perimeter (Figs 6b±d); however, in HaCaT cells, nuclei were
brightly labeled (Fig 6a). Labelling for matrilysin, stromelysin-1,
and TIMP-1 in all four cell lines appeared more intense in mitotic
cells.
Figure 2. Steady-state levels of mRNA for metalloproteinases
and TIMPs. Mean and SD for two RT-PCR reactions for each
mRNA. (a) Matrilysin and stromelysins 1, 2, and 3; (b) TIMP-1; (c)
TIMP-3.
Figure 3. Immunoblots of metalloproteinases and TIMP in
conditioned medium. Culture medium from each cell line was
collected after 48 h incubation. Expression of speci®c proteins was
analyzed by gel electrophoresis and immunoblotting. Approximate
molecular weights listed were determined by comparison with molecular
weight standards. MMP2 = gelatinase A, 66 kDa; MMP3 = stromelysin-
1, 59 kDa and 48 kDa; MMP7p = promatrilysin, 28 kDa; MMP7a =
active matrilysin, 38 kDa aggregate; MMP9 = gelatinase B, 83 kDa;
MMP10 = stromelysin-2, 50 kDa; MMP11 = stromelysin-3, 47 kDa.
TIMP1 = 28.5 kDa.
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Figure 4. Immunocytochemistry for active
matrilysin. All cells were ®xed 24 h after
removal of aphidicolin. Arrowheads designate
mitotic cells. (a) HaCaT; (b) SiHa; (c) FaDu;
(d)A431. Scale bar: 100 mm.
Figure 5. Immunocytochemistry for stromelysin-
1. All cells were ®xed 24 h after removal of
aphidicolin. Arrowheads designate mitotic cells. (a)
HaCaT; (b) SiHa; (c) FaDu; (d) A431. Scale bar:
100 mm.
Figure 6. Immunocytochemistry for TIMP1.
All cells were ®xed 24 h after removal of
aphidicolin. Arrowheads designate mitotic cells. (a)
HaCaT, large cell at top of ®gure is binucleate; (b)
SiHa; (c) FaDu; (d) A431. Arrowhead at bottom of
®gure designates daughter cells in cytokinesis. Scale
bar: 100 mm.
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DISCUSSION
Metalloproteinases have been shown to promote tumor progression
through several mechanisms (reviewed in Kleiner and Stetler-
Stevenson, 1999; Sternlicht et al, 2000). Increased metalloprotei-
nase activity increases tumor cell invasiveness through extracellular
matrix (Knox et al, 1998), and treatment with TIMP inhibits both
metalloproteinase activity and invasiveness (Umenishi et al, 1991;
DeClerck et al, 1992; Liu et al, 1997); however, at least one
metalloproteinase, stromelysin-3, does not digest matrix, but
promotes tumor growth by blocking cell death in malignant cells
(Boulay et al, 2001). Matrilysin and gelatinase A are thought to play
a role in tumor initiation rather than invasiveness (Meade-Tollin et
al, 1998). Metalloproteinase degradation of extracellular matrix may
release matrix-associated growth factors that stimulate tumor cell
proliferation (Vlodavsky et al, 1990). Conversely, contact with
particular matrix proteins can suppress tumor cell proliferation,
which is enhanced when these matrix components are degraded
(Henriet et al, 1999). Additionally, matrilysin and stromelysin-1 can
cleave E-cadherin, thereby increasing tumor cell invasiveness by
blocking cell adhesion (NoeÈ et al, 2000).
In normal cells and tissues, metalloproteinases also carry out
routine tasks such as matrix repair and remodeling, but few
metalloproteinases are associated with unique functions, and most
participate in similar tasks. Certain metalloproteinases can also
exhibit an inhibitory effect on tumorigenesis through an effect on
angiogenesis. Matrilysin, stromelysin-1, and murine macrophage
elastase (MME, MMP-12) are capable of cleaving plasminogen
in vitro to yield angiostatin, which blocks endothelial cell prolif-
eration. In tumor tissue, conversion of plasminogen to angiostatin is
carried out by macrophage metalloproteinases. MME has been
shown to be critical for the production of angiostatin, as MME-null
macrophages are incapable of converting plasminogen to angios-
tatin (Cornelius et al, 1998).
This study focuses on the effects of metalloproteinases on
invasiveness. By comparing the types of active metalloproteinases
released by invasive tumor cells to those produced by normal cells
or noninvasive tumor cells, the particular metalloproteinases that
contribute to tumor cell invasiveness in different types of cancer can
be identi®ed. Matrigel invasion was used to assess invasiveness. The
Matrigel assay revealed at least two components to invasiveness:
inherent cell mobility, determined by the ability of cells to pass
through uncoated ®lters; and ability to invade Matrigel. Of the
three SCC cell lines, both FaDu and A431 showed greater mobility
than HaCaT, the noninvasive, nontumorigenic keratinocyte line;
however, only FaDu cells demonstrated signi®cantly greater
invasion of Matrigel than HaCaT cells, indicating that cell mobility
alone does not regulate invasiveness in SCC cells. Differences in
cell mobility may re¯ect the different origins of the cell lines.
HaCaT is a keratinocyte line and the A431 line is derived from an
epidermal SCC, whereas FaDu and SiHa cells are derived from
mucosal SCC. Batimastat-treated HaCaT, FaDu, and A431 cells
were less active in passing through uncoated ®lters, suggesting that
metalloproteinase activity contributes to cell mobility. Batimastat
treatment, however, signi®cantly decreased Matrigel invasion only
in FaDu cells, con®rming that invasiveness in this cell line requires
metalloproteinase activity.
Because Batimastat does not act speci®cally on any particular
metalloproteinase, expression of speci®c metalloproteinases was
examined and compared among the four cell lines. No correlation
was found between steady-state levels of mRNA for any particular
metalloproteinase and invasiveness, indicating that regulation of
invasiveness occurs at a post-transcriptional step, such as metallo-
proteinase synthesis or activation. Matrilysin and stromelysin-3
mRNA levels were similar in all four cell lines, but neither
promatrilysin nor active matrilysin was detected in conditioned
medium from HaCaT cells, whereas varying amounts of matrilysin
and stromelysin-3 protein were found in medium from each of the
four cell lines. Meade-Tollin et al found that matrilysin mRNA
levels increased in noninvasive transformed HaCaT cells, but not in
the invasive transformants. They further observed that secretion of
matrilysin nonetheless increases in invasive transformants, and also
concluded that post-transcriptional regulation of matrilysin expres-
sion contributes to the invasive phenotype (Meade-Tollin et al,
1998).
A431 cells had the lowest steady-state levels of stromelysin-1
mRNA, but higher levels of stromelysin-1 protein in conditioned
medium than HaCaT or SiHa cells. No difference was seen in
levels of mRNA for TIMP-1 among the four cell lines, yet no
TIMP-1 protein was found in conditioned medium from HaCaT
cells. These results provide further support for post-transcriptional
regulation of metalloproteinase and TIMP activity. TIMP-3
mRNA was present in all four cell lines, but no TIMP-3 protein
was detected in conditioned medium from any cell line. This result
was unexpected because the localization of matrilysin and TIMP-3
in skin is similar in vivo (Airola et al, 1998). TIMP-3 binds strongly
to extracellular matrix, however, and so may not have been
extracted in conditioned medium (Woessner, 2001). Alternatively,
TIMP-3 may be not synthesized or secreted by these cell lines
in vitro, or is produced in amounts that could not be detected by
immunoblotting.
Matrilysin has been implicated in promoting tumorigenesis as
well as invasiveness. In colon carcinoma cell lines, speci®c
inhibition of matrilysin activity reduces both tumorigenicity and
tumor invasiveness; however, transfection of matrilysin into cells
that do not express the enzyme increased tumorigenicity but not
invasiveness (Witty et al, 1994). Thus, whereas matrilysin does not
drive invasiveness in these cell types, it nonetheless contributes to
invasion and metastasis in colon carcinoma. In our study, media
from FaDu and A431 cells, the cell lines with greatest cell mobility,
contained the highest amounts of gelatinase A, promatrilysin, and
active matrilysin. No matrilysin was detected by immunoblotting in
medium from HaCaT cells. Similar results were observed in
transformed HaCaT cells: little or no matrilysin or gelatinase A was
released into the medium by nontransformed cells, and the greatest
amounts of these two enzymes were found in medium from
transformed cells with an invasive, SCC phenotype (Bachmeier et
al, 2000). Therefore, matrilysin and gelatinase A appear to function
in tumorigenesis and cell mobility, and contribute to, but do not
trigger invasiveness in SCC cells.
Gelatinase B mRNA is expressed by tumor cells at the interface
between tumor and stromal cells in SCC, but is not expressed by
tumor cells in BCC or by normal skin cells (Pyke et al, 1992;
Tsukifuji et al, 1999). Immunoblotting experiments revealed that
HaCaT cells secrete the greatest amount of active gelatinase B,
whereas the enzyme is barely detectable in medium from the SCC
cell lines. Others have used zymography to show that HaCaT and
transformed HaCaT cells secrete gelatinase B, but they did not
demonstrate a correlation between invasiveness and gelatinase B
secretion. (Meade-Tollin et al, 1998; Bachmeier et al, 2000).
Within our experimental system, active gelatinase B secretion does
not correlate with SCC invasiveness, as medium from the invasive
cell line, FaDu, contained the least amount of active gelatinase B.
The most notable difference among the four cell lines was the
release of active stromelysin-1 only by FaDu cells. Active
stromelysin-1 could not be detected in conditioned medium
from HaCaT, SiHa, or A431 cells. Bachmeier et al also detected
weak production of prostromelysin-1 by HaCaT cells. In the
transformed HaCaT cells, invasive cells produced much greater
amounts of active stromelysin-1 than benign cells (Bachmeier et al,
2000). In vivo, keratinocytes in normal skin do not express
stromelysin-1, but expression is stimulated by wounding
(Windsor et al, 1993; Saarialho-Kere et al, 1994). In SCC,
stromelysin-1 expression is associated with advanced pathology
and metastasis (Muller et al, 1991; Kusukawa et al, 1996; Tsukifuji et
al, 1999). Stromelysin-1 also affects both tumorigenesis and
invasiveness in some cancer cells. In stromelysin-1-transfected
mammary epithelial cells, stromelysin-1 induction leads to
phenotypic changes characteristic of tumor cells (Lochter et al,
1997; Sternlicht et al, 2000). In DMBA-TPA-induced SCC in
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mouse skin, stromelysin-1 expression in tumor cells is coincident
with the epithelial-to-mesenchymal transition that yields invasive,
metastatic tumor cells (Wright et al, 1994). Stromelysin-1 can
activate matrilysin and cleave E-cadherin, releasing a soluble E-
cadherin fragment that blocks E-cadherin function (Imai et al, 1995;
NoeÈ et al, 2000). Thus, in addition to digesting extracellular matrix,
active stromelysin-1 can enhance basal lamina degradation by
matrilysin and facilitate invasion and metastasis by disrupting cell±
cell and cell±matrix attachment. Active stromelysin-1 accordingly
plays a key role in invasiveness, and our results suggest that
activation of stromelysin-1 is an important regulatory step for
invasiveness in SCC cells.
FaDu cells also released substantially greater amounts of
stromelysins 2 and 3 into conditioned medium than the other
cell lines. Both enzymes were barely detectable in SiHa medium,
and stromelysin-3 was weakly detected in HaCaT and A431
medium. Because stromelysin-2 secretion was greatest in medium
from HaCaT and FaDu cells, production of this metalloproteinase
does not correlate with invasiveness. SCC tissue also expresses
stromelysin-2 mRNA, which is transcribed in vivo by epithelial and
tumor cells, but expression of this metalloproteinase is associated
with tissue in¯ammation rather than tumor cell invasiveness in skin
cancer (KerkelaÈ et al, 2001). Stromelysin-2 can activate matrilysin
and gelatinase B, however, and may contribute to tumor
invasiveness through these enzymes (Nakamura et al, 1998).
Although stromelysin-3 secretion was greatest in the invasive cell
line, FaDu, this metalloproteinase does not digest matrix proteins
and is unlikely to play a direct role in invasiveness (Murphy et al,
1993; Pei and Weiss, 1995). Instead, stromelysin-3 appears to foster
the growth of tumors by blocking cell death and promoting
implantation of malignant epithelial cells (Masson et al, 1998;
Boulay et al, 2001).
Stromelysin-3 mRNA is expressed in head and neck SCC, but
not in normal tissues from the head and neck. In SCC tissue,
stromelysin-3 mRNA and protein was found only in ®broblasts
surrounding invasive cancer cells and not in tumor cells, suggesting
a paracrine effect on tumor cells (Muller et al, 1993; Thewes et al,
1998). We have demonstrated stromelysin-3 production in HaCaT
and SCC cell lines, however, and Bachmeier et al have shown that
this metalloproteinase is expressed by HaCaT and transformed
HaCaT cell lines (Bachmeier et al, 2000). Similarly, in skin cancer
tissue, gelatinase A mRNA is expressed by stromal cells adjacent to
tumor nodules in SCC and BCC, but is not expressed by tumor
cells (Pyke et al, 1992; Tsukifuji et al, 1999), yet SCC cell lines
produce gelatinase A in vitro. Normal keratinocytes do not
synthesize stromelysin-1 in vivo, but HaCaT cells in vitro do
produce stromelsyin-1 (Windsor et al, 1993; Saarialho-Kere et al,
1994). Paracrine regulatory factors present in tissue are likely to
explain the difference between stromelysin-3 and gelatinase A
expression by cell lines in vitro and cells in vivo.
Cell-associated labeling for matrilysin, stromelysin-1, and TIMP-
1 appeared to increase in mitotic cells, particularly in metaphase.
The apparent increase may result from a change in shape as cells
round up for cell division. Alternatively, these results may indicate a
correlation between cell cycling and metalloproteinase or TIMP
expression. Henriet et al have shown that plating melanoma cells on
collagen I elevates expression of p27KIP1´, and arrests the cells in G1
of the cell cycle (Henriet et al, 1999). TIMP-1 localization to the
nucleus has also been shown to be cell-cycle dependent in gingival
®broblasts (Zhao et al, 1998). Therefore it is not unreasonable to
hypothesize an association between metalloproteinase activity and
the cell cycle. Nuclear localization of TIMP-1 was also observed in
HaCaT cells in this study. Whereas precise phases of the cell cycle
were not distinguished in these assays, nuclear localization of
TIMP-1 was seen in HaCaT cells at all time points after removal of
aphidicolin and was pronounced in aphidicolin-blocked cells that
arrest in G1 (data not shown). Less dramatic nuclear expression of
TIMP-1 was also observed in SiHa cells. Because neither of these
two cell lines was able to invade Matrigel, it can be speculated that
TIMP-1 has a nuclear function that affects cell mobility and
invasiveness.
This study is not intended to be a comprehensive examination of
the role of all known metalloproteinases in invasiveness. It is also
limited to an in vitro model system. Other metalloproteinases may
also play important roles in various aspects of tumorigenesis in vivo,
including invasiveness. For example, the recently described
collagenase-3 (MMP-13) can also degrade basement membrane
components and may function in invasiveness. In head and neck
SCC in vivo, collagenase-3 mRNA is expressed by tumor cells
found on the leading edge of the tumor that are in contact with
stromal ®broblasts (Johansson et al, 1997). In laryngeal SCC,
collagenase-3 expression correlates with overexpression of gelati-
nase A and MT-1-MMP, suggesting a cooperative effect of these
enzymes on tumor progression (Cazorla et al, 1998). We hope that
our results on the expression of stromelysins and matrilysin in
invasive SCC cell lines will stimulate further research on the
functions of stromelysin-1 and other metalloproteinases in tumor
cell invasiveness, and on the mechanisms through which these
enzymes facilitate tumor cell invasion and metastasis in vivo.
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